Sun Pharma Partners to Bring Innovative Stroke Drug Tyvalzi™ to India

14 Sep 2023 , 01:32 PM

Sun Pharmaceutical Industries Limited has entered into a license agreement with Pharmazz Inc., a U.S.-based biopharmaceutical company, to introduce the innovative drug Tyvalzi™ (Sovateltide) to the Indian market. Tyvalzi™ is designed to treat cerebral ischemic stroke and is a first-in-class drug developed by Pharmazz for potential global use.

Under the agreement, Sun Pharma gains exclusive marketing rights for Sovateltide in India, where it will be marketed under the brand name Tyvalzi™ (Sovateltide). Pharmazz will receive upfront payments, milestone payments, and ongoing royalties as part of this collaboration.

Clinical trials in India’s Phase 3 for Tyvalzi™ have shown promising results, with statistically and clinically significant improvements in neurological outcomes for ischemic stroke patients. Unlike existing treatments with a narrow 4-5 hour window, Tyvalzi™ can be administered within 24 hours post-stroke.

Dr. B. S. Paul, a leading neuro-physician involved in the clinical trials, highlighted the pressing need for new stroke therapies, as stroke is a significant global cause of morbidity and mortality.

Dr. Prof. Anil Gulati, CEO, and Chairman of the Board of Directors of Pharmazz, expressed enthusiasm for the partnership with Sun Pharma, India’s largest pharmaceutical company, to introduce Tyvalzi™ (Sovateltide) to the Indian market.

Stroke is a significant health concern in India, with a high incidence rate estimated at 116 to 163 cases per 100,000 population. It ranks as the fourth leading cause of death and the fifth leading cause of disability in the country.

This partnership aims to address the critical medical need associated with cerebral ischemic stroke in India, potentially benefiting a substantial number of affected individuals. Sun Pharmaceutical Industries Limited owns the brand name Tyvalzi™.

For feedback and suggestions, write to us at [e-mail].